Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)

Trial Profile

Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Cerebral haemorrhage
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top